{"id":"NCT01721681","sponsor":"Bio Products Laboratory","briefTitle":"A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years","officialTitle":"A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL's High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2012-11-06","resultsPosted":"2018-03-07","lastUpdate":"2018-04-02"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Factor X Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"FACTOR X","otherNames":[]}],"arms":[{"label":"FACTOR X","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to assess the efficacy of FACTOR X in the prevention of bleeding when given as routine prophylaxis over 12 months.\n\nThe secondary objectives of the study are:\n\n1. To assess the pharmacokinetics of FACTOR X after a single dose of 50 IU/kg.\n2. To assess the safety of FACTOR X when given as routine prophylaxis over 6 months (26 weeks).","primaryOutcome":{"measure":"The Number of Participants With Excellent Reduction in Bleeding When Given FACTOR X as Routine Prophylaxis Over 6 Months","timeFrame":"6 months","effectByArm":[{"arm":"Overall Study","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["Aneamia","Cough","High Temperature/Fever","Cold","Headache"]}}